Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 1/20 | 0.57 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | TK1 | P04183 | 6/20 | 0.42 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20180391 | 0.92 | DHFR (0.58) | DHFRBCHETK1RNASE1 | |
| SCHEMBL20180384 | 0.92 | DHFR (0.58) | DHFRBCHETK1RNASE1 | |
| SCHEMBL20180461 | 0.92 | DHFR (0.58) | DHFRBCHETK1RNASE1 | |
| SCHEMBL20180389 | 0.92 | DHFR (0.58) | DHFRBCHETK1RNASE1 | |
| SCHEMBL20180532 | 0.92 | DHFR (0.58) | DHFRBCHETK1RNASE1 | |
| SCHEMBL23621017 | 0.92 | DHFR (0.58) | DHFRBCHETK1RNASE1 | |
| SCHEMBL20180392 | 0.92 | DHFR (0.58) | DHFRBCHETK1RNASE1 | |
| SCHEMBL20180458 | 0.92 | DHFR (0.58) | DHFRBCHETK1RNASE1 | |
| SCHEMBL20180462 | 0.92 | DHFR (0.58) | DHFRBCHETK1RNASE1 | |
| SCHEMBL20180386 | 0.92 | DHFR (0.58) | DHFRBCHETK1RNASE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11730748-B2 | Cyclic phosphate substituted nucleoside derivatives for the treatment of liver diseases | MSD INTERNATIONAL GMBH (CH) | 2023-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11730748-B2 | Cyclic phosphate substituted nucleoside derivatives for the treatment of liver diseases | SLC10A1, PNP, PYGL | DHFR 597/4885BCHE 1541/4885TK1 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.